We used human bladder cancer as a model system and the whole-organ histologic and genetic mapping strategy to identify clonal genetic hits associated with growth advantage, tracking the evolution of bladder cancer from intraurothelial precursor lesions. Six putative chromosomal regions critical for clonal expansion of intraurothelial neoplasia and development of bladder cancer were identified by using this approach. Focusing on one of the regions, which includes the model tumor suppressor RB1, we performed allelotyping of single-nucleotide polymorphic sites and identified a 1.34-Mb segment around RB1 characterized by a loss of polymorphism associated with the initial expansion of in situ neoplasia. This segment contains several positional candidate genes referred to by us as forerunner genes that may contribute to such expansion. We subsequently concentrated our efforts on the two neighbor genes flanking RB1, namely ITM2B and CHC1L, as well as P2RY5, which is located inside RB1. Here, we report that ITM2B and P2RY5 modulated cell survival and were silenced by methylation or point mutations, respectively, and thus by functional loss may contribute to the growth advantage of neoplasia. We also show that homozygous inactivation of P2RY5 was antecedent to the loss of RB1 during tumor development, and that nucleotide substitutions in P2RY5 represent a cancer predisposing factor.
M
any common epithelial cancers, including those arising in the bladder, begin as clonal in situ expansion of neoplastic cells, which show no or minimal deviation from the normal phenotype (1) (2) (3) (4) . Such lesions often form plaques involving large areas of the affected mucosa, and their expansion precedes the development of microscopically recognizable dysplasia or carcinoma in situ (4, 5) . Identification of chromosomal regions associated with the initial expansion of neoplasia is a requisite for more specific studies of their positional candidate genes that may drive the initial clonal expansion of neoplasia.
We have used an approach referred to as whole-organ histologic and genetic mapping (WOHGM) to identify clonal hits associated with growth advantage, tracking the evolution of human bladder cancer from occult in situ lesions to invasive disease on a total genomic scale (6) (7) (8) . Human bladder carcinoma was used as a model of common epithelial malignancy that develops by progression of microscopically recognizable intraurothelial preneoplastic lesions ranging from mild dysplasia to carcinoma in situ (5) . Bladder cancer was also selected because it is close to an ideal model human tumor to study the early events of carcinogenesis due to simple anatomy of the organ and the ease in mapping preneoplastic conditions geographically across the entire mucosa of cystectomy specimens (9) (10) (11) .
In this paper, we begin by presenting the identification of the six critical chromosomal regions that may contain genes driving the development of bladder cancer. Then, we focus on one of the regions, which contain the model tumor suppressor RB1, and by performing high-resolution mapping with SNPs, we identified alternative target genes subsequently referred to by us as forerunner (FR) genes that may contribute to the development of in situ urothelial neoplasia. Finally, we provide evidence that their loss of function is likely to be critical to the initial clonal expansion of in situ neoplastic lesions.
Results and Discussion
To identify chromosomal regions that may contain genes most relevant for the development of the initial clonal expansion of neoplasia, we performed the genome-wide WOHGM on human cystectomy specimens with transitional cell carcinoma (TCC) using 787 hypervariable DNA markers (mostly microsatellites) mapping to autosomes 1-22. By using this approach, we identified chromosomal regions characterized by clonal loss of heterozygosity (LOH) that had a geographic relationship to the distribution of two major types of intraurothelial precursor lesions [supporting information (SI) Fig. 6 ]. The first group consisted of alterations associated with expansion of a dominant clone with minimal or no phenotypic change that involved large areas of bladder mucosa. The second group consisted of alterations associated with the development of successive clones showing a fully transformed phenotype (i.e., those related to severe dysplasia/carcinoma in situ with subsequent progression to invasive cancer). We identified clonal LOH with both characteristics in four of the five tested bladders, with each one showing a unique combination of changes (SI Fig. 7) . However, when constellations of putative critical losses from the individual bladders were analyzed, it became evident that six chromosomal regions, mapping to 3q22-3q24, 5q22-5q31, 9q21-9q22, 10q26, 13q14, and 17p13, were involved in more than one case and could represent six regions critical for the initial clonal expansion of urothelial neoplasia (Fig. 1 ). This observation was confirmed by testing multiple microsatellite markers mapping to the six chromosomal regions on voided urine and peripheral blood from 32 patients with clinically evident bladder cancer and from 31 patients with a history of bladder tumors who were disease free at the time of urine collection (SI Fig. 8 b-d) . LOH affecting at least one of the regions was identified in 98% of these patients, and a similar frequency of LOH was present in patients with a history of TCC as well as those with clinically evident disease. In 82% of the cases, synchronous involvement of two to five chromosomal regions was present, and this confirmed that losses in these regions were frequent in bladder cancers and thus may contain genes critical for its development (SI Fig. 8d) .
To identify prototypic genes that may drive such expansion, we concentrated our efforts on the 13q14 region, which contains the model tumor suppressor gene, RB1 (12) . We have previously reported that the patterns of RB1 inactivation and LOH in this region suggest that RB1 is not providing growth advantage for in situ urothelial neoplasia, whereas other genes in the region may drive the initial expansion of bladder neoplasia (13) . This observation was based on low-resolution microsatellite and limited SNP mapping, which did not permit the precise identification of the involved region and its candidate genes. To map the positional candidate genes involved in the initial clonal expansion of urothelial neoplasia, we performed high-resolution whole-organ SNP-based allelotyping of the 27-megabase (Mb) segment around RB1 (13, 14) (SI Fig. 9 ). When the integrated whole-organ maps of loss of polymorphism (LOP) identified by SNPs and maps of LOH identified by microsatellite markers were compared with RB1 sequencing data and RB protein expression patterns, it became evident that LOH/LOP that affected RB1 and its flanking regions was an early event in bladder neoplasia ( Fig. 2 and SI Fig. 10 ). This loss was associated with initial clonal expansion that formed a plaque involving large areas of bladder mucosa and was never associated with the inactivation of the second RB1 allele. In those cases in which loss of one RB1 allele was associated with the mutational inactivation of the second allele, this inactivation was a later event corresponding to the onset of severe dysplasia/carcinoma in situ progressing to invasive carcinoma.
The patterns of integrated LOH and LOP identified by microsatellite and SNP markers from five cystectomy specimens defined the minimal region associated with clonal expansion of in situ neoplasia, which involved a 1.34-Mb segment around 
RB1.
¶ ¶ Because this region was defined by WOHGM of only five cystectomies, we further investigated the frequency of its involvement on 84 paired samples of bladder tumors and peripheral blood DNA by allelotyping of 92 SNPs mapping to a 3.16-Mb segment around RB1 (Fig. 3) . The position of the segment with the most frequent LOP identified by this approach overlapped with the position of the region associated with clonal expansion initially found by WOHGM. (For details, see SI Text.) These data further supported the hypothesis that genes located near the model tumor suppressor, RB1, subsequently referred to by us as FR genes, may significantly contribute to the development of bladder cancer. By analyzing the predicted functions of their encoded proteins, we decided to concentrate our initial efforts on the two nearest neighbor genes flanking RB1, namely ITM2B, which encodes a mitochondrial membrane protein with a Bcl-2 homology 3 (BH3) domain (15) , CHC1L (RCBTB2), which encodes a guanine nucleotide exchange factor protein for the ras-related GTPase (16) , and P2RY5 located within intron 17 of RB1, which encodes a G protein-coupled receptor (17) .
To investigate the involvement of these candidate FR genes in bladder carcinogenesis, we initially analyzed their sequence and expression in 12 bladder cancer cell lines and 14 paired samples of adjacent urothelium and TCCs. The initial sequencing of bladder cancer cell lines as well as paired samples of adjacent urothelium and TCCs did not identify mutations within FR genes. However, by sequencing DNA from tumors and surface urothelium of the five resected bladders used for WOHGM as well as paired peripheral blood DNA, we found a germ-line deletion of G at codon 296 of the predicted P2RY5 protein (Fig.  4a) ; the resulting frameshift producing a stop signal at codon 302. In addition, this germ-line mutation was associated with LOP involving a 1.27-Mb segment in the surface urothelium of bladder mucosa (Fig. 4 b-d and SI Fig. 11 ). Consequently, this loss homozygously inactivated P2RY5 in the urothelium (Fig. 4c) , whereas the remaining alleles of ITM2B, RB1, and CHC1L were wild type. The homozygous inactivation of P2RY5 was associated with expansion of an in situ neoplastic clone involving large areas of bladder mucosa and the subsequent development of multifocal TCC. Evidence was thus provided that P2RY5 rather than RB1 was a target for mutations within the 1.27-Mb segment in the 13q14 region and was likely involved in the initial expansion of the in situ neoplastic clone.
We subsequently found that the FR genes were downregulated in bladder cancer cell lines with inactivated RB1 as well as in those cell lines with wild-type RB1 (SI Fig. 12a) . Typically, more than one candidate FR gene was down-regulated, and the reduction of expression was often Ͼ4-fold (Ͼ75%). The FR genes were often down-regulated in both superficial and invasive TCCs and in corresponding samples of adjacent surface urothelium, again suggesting their involvement in early in situ phases of bladder neoplasia (SI Fig. 12b ). To rule out the possibility of nonspecific down-regulation of the candidate FR genes in the ¶ ¶ LOP by SNP mapping was identified in all five cystectomy specimens, including the specimen in which WOHGM mapping with microsatellites did not reveal LOH involving 13q14 region. The black line depicts the area of LOP involving the 1.27-Mb segment; the blue line delineates the area with P2RY5 showing the deletion at codon 296. TCC1-3 designate separate foci of carcinoma. The code for the histologic map is shown in Fig. 2. urothelium, the expression pattern of 29 genes around RB1 was analyzed. These studies were performed on the same 12 bladder cancer cell lines and showed that the candidate FR genes were the most significantly and frequently down-regulated genes within the distance of Ϸ3 Mb around RB1 (data not shown).
Because the 5Ј regions of ITM2B and CHC1L have typical CpG islands, we further investigated whether methylation of their putative promoter regions was a mechanism responsible for silencing these genes (SI Fig. 13) . Hypermethylation of the ITM2B promoter was identified in 6 of 12 bladder cancer cell lines and, in each instance, was associated with Ͼ2-fold (Ͼ50%) reduction in gene expression (SI Fig. 12a) . Expression of ITM2B could be restored by treatment with the DNA methylation inhibitor 5-aza-2Ј-deoxycytidine, confirming that methylation was involved in silencing of this gene. The analysis of 14 paired samples of adjacent urothelium and TCC confirmed these observations and documented that methylation of ITM2B could be detected in 64% of tumor samples, which was also present in the adjacent urothelium (SI Fig. 12b) . No abnormal pattern of methylation of CHC1L was identified.
To address how frequently the candidate FR genes are involved in bladder carcinogenesis, we performed methylationspecific PCR and sequencing analyses of ITM2B and P2RY5 on an additional 195 TCCs and an equal number of controls matched for age, sex, and ethnicity. In addition, paired nontumor DNA from the same patient in 131 of the TCCs was also sequenced. Methylation of ITM2B followed the trend identified in bladder cancer cell lines or paired adjacent urothelium and tumor samples being detected in 40% of TCC. It was equally frequent in low-grade (grade 1-2) superficial (T a -T 1a ) as in high-grade (grade 3) invasive (T 1b and higher) TCCs. Missense point mutations of P2RY5 were found in 7% of TCCs and, of particular importance, some of these were documented as germ-line alterations ( Fig. 5a and SI Table 2 ). The mutations of P2RY5 (somatic and germ-line) identified in bladder tumor samples and paired nontumor DNA from the same patient were not present in unaffected control samples or in the human genome SNP databases.
Although missense mutations in P2RY5 were fairly rare, we also detected three polymorphic sites in P2RY5, namely 1386 T-C, 1602 A-C, and 1722 G-T. A 1722 G-T polymorphism resulting in the substitution of tryptophan for cysteine at position 307 was of potential importance because it was detected in several bladder tumors and nontumor DNA from the same patient. In addition, molecular models of P2RY5 protein developed by using its homology to rhodopsin suggest that this substitution involving the cytoplasmic domain of the protein may affect its interaction with the G protein complex and compromise its biological activity (18) (19) (20) (21) (22) (23) (Fig. 5b) . In fact, the loss of apoptotic activity for the 1722 T variant allele was documented by in vitro transfection assays (see below). Therefore, we extracted DNA from laser microdissected surface bladder urothelium with in situ neoplasia adjacent to invasive TCC from a patient with 1722 G-T polymorphism. By using allele-specific pyrosequencing, we showed that loss of a wild-type 1722 G P2RY5 allele with retention of the variant 1722 T P2RY5 allele occurred in in situ phase of bladder neoplasia and preceded the loss of RB protein expression (Fig. 5 c and d) .
To further investigate the role of a 1722 G-T polymorphism of P2RY5 in the development of bladder cancer, we conducted a case-control study on peripheral blood DNA from 790 patients with bladder cancer and 712 age-and sex-matched controls. The heterozygous 1722 G-T P2RY5 genotype was identified in 2.78% of bladder cancer patients and 2.81% of controls. We did not identify any individuals with a homozygous 1722 T-T genotype. In addition, the presence of 1722 G-T genotype was not associated with an overall higher risk for bladder cancer (adjusted odds ratio, 1.07; 95% confidence interval, 0.57-2.03). However, it appeared that smoking modulates the effect of this polymorphism and all 1722 G-T carriers who were smokers developed bladder cancer (odds ratio not calculable). This strongly suggests that exposure to tobacco smoking-related carcinogens in the presence of a 1722 T P2RY5 allele synergistically increases the risk for bladder cancer. Details concerning the frequency of LOP, RB1, and FR Collectively, our data strongly suggest that loss of FR gene function promotes early clonal expansion, presumably by directly regulating cell proliferation and/or cell death. Indeed, analysis of the ITM2B sequence identified a putative BH3 domain, a sequence motif that mediates the proapoptotic functions of an important family of cell-death regulators (24) . To test this hypothesis, we transiently transfected ITM2B and P2RY5 expression constructs into the ITM2B-and P2RY5-deficient UC6 bladder cancer cell line, which showed Ͼ4-fold down-regulation of both genes but has wild-type RB1 (SI Fig. 14) . Because human urothelial and bladder cancer cells express alternatively spliced long (L) and short (S) variants of ITM2B (data not shown), the experiments were performed with the constructs containing ITM2BL and ITM2BS inserts. Because ITM2BS was previously shown to be the apoptotically active form of ITM2B protein and this activity was attributed to an unmasked BH3 domain (15), we performed additional experiments with constructs containing inactivating mutations within its BH3 domain. These included constructs with: (i) substitutions involving two conserved amino acids at positions 35 and 40; (ii) substitutions of eight amino acids at positions 34-41; and (iii) a deletion of the entire predicted BH3 domain involving amino acids at positions 31-45 (SI Fig.  14a ). To verify that nucleotide substitutions of P2RY5 identified in clinical samples alter its function, we developed additional constructs containing mutant P2RY5 inserts. These included constructs with: (i) a deletion of G at codon 296 causing a frameshift with downstream stop signal at codon 302 identified as a homozygous mutation in one of the cystectomies used for WOHGM (see Fig. 4 ) and (ii) a 1722 T variant allele resulting in the amino acid substitution at position 307 involved in the 1722 G-T polymorphism (see Fig. 5 ).
Ectopically driven expression of a wild-type ITM2BS, as well as of a wild-type P2RY5, reduced rates of proliferation in recipient cells (SI Fig. 14 c and d) . These effects were associated with induction of apoptosis as measured by specific proteolytic processing of procaspase-3 and DNA fragmentation (SI Fig. 14  b, e, and f) . In contrast, mutant ITM2BS constructs lacking a functional BH3 domain had no effect on caspase activation or DNA fragmentation (SI Fig. 14 b, e, and f) . Transfections with a wild-type ITM2BL showed no evidence of apoptotic activity. Similarly, transfections with constructs containing mutant P2RY5 inserts showed that nucleotide substitutions identified in cancer samples including a substitution associated with 1722 G-T polymorphism abolished its apoptotic effect. Transfections with a wild-type CHC1L construct showed no effect on cell proliferation or survival (data not shown).
Our findings support the existence of distinct genes, referred to by us as FR genes, mapping contiguously to RB1. Similar genes may also be present in the remaining five chromosomal regions we have identified. The FR genes are related to tumor suppressors in the sense that they appear to contribute to tumorigenesis by loss of function, but their inactivation precedes the functional loss of tumor suppressors such as RB1 during tumor development. In fact, we have documented sequential homozygous inactivation of a candidate FR gene P2RY5 and RB1 in the development of bladder cancer. Although the mutational inactivation of this candidate FR gene is rare, it provides strong evidence supporting its involvement in early phases of bladder neoplasia. In addition, a 1722 G-T polymorphism in P2RY5 was associated with an increased risk for bladder cancer development when combined with the exposure to tobacco smoking. Moreover, epigenetic silencing of another candidate FR gene, ITM2B, by methylation appears to be a frequent occurrence responsible for silencing of this gene in bladder carcinogenesis. In this scenario, the FR genes provide the initial growth advantage for a neoplastic clone, whereas subsequent inactivation of tumor suppressors is a transforming event associated with the development of a successor clone with features of severe dysplasia/ carcinoma in situ. Because in some cases allelic loss associated with clonal expansion of in situ neoplasia involved not only FR genes but also RB1, the possibility that RB1 haploinsufficiency might play a role in the development of premalignant lesions in these cases cannot be excluded. However, survivors with hereditary retinoblastoma carrying only one wild-type copy of RB1 in their somatic cells develop normally, and they do not show hyperproliferative changes in the urinary tract or in any other normal tissue including the retina (25) . In addition, otherwise normal human cells carrying only one copy of the wild-type RB1 gene do not show increased growth rates or transformed phenotype in vitro compared with the cells carrying two copies of the wild-type RB1 gene (26) . These data indicate that RB1 haploinsufficiency is unlikely to provide a significant growth advantage either in vivo or in vitro. It is uncertain at this time whether the FR genes provide growth advantage in the state of haploinsufficiency or they contribute to tumor development after their homozygotic inactivation. The overall pattern of LOH/LOP identified by our mapping studies suggests that multiple FR genes from several chromosomal regions are involved in the development of neoplasia in vivo. The FR genes not only provide a new paradigm for cancer development but may also represent early detection and risk markers as well as targets for therapeutic and preventive interventions.
Materials and Methods

Details of Materials and Methods are described in SI Text.
Mapping Strategy. WOHGM with microsatellites and SNP markers was performed on cystectomies from five patients with high-grade (grade 3) invasive TCC according to previously published protocols (6-8, 13, 14) . In brief, testing was performed on 234 DNA samples corresponding to areas with the following: microscopically normal appearing urothelium (NU; n ϭ 53), low-grade intraurothelial neoplasia (LGIN; n ϭ 82), high-grade intraurothelial neoplasia (HGIN; n ϭ 50), and invasive TCC (n ϭ 49). Initially, all 787 markers were tested on paired DNA samples from TCC and nontumor DNA. LOH was identified in 196 markers that were subsequently tested on all mucosal samples of five cystectomies. The frequencies of LOH in the six critical chromosomal regions associated with clonal expansion of in situ bladder neoplasia identified by WOHGM were additionally tested on paired voided urine and peripheral blood samples of 63 patients with bladder cancer. Then, we focused on one of the regions and performed high-resolution WOHGM by using 661 SNPs mapping within a 27-Mb segment around RB1. Initially, all 661 SNPs were tested on normal genomic DNA. Then, those SNPs that exhibited polymorphism were tested on representative DNA samples corresponding to invasive TCC of the same individual. Finally, those SNPs that showed LOP were tested on all mucosal samples of the same cystectomy.
For the 13q14 region, the results of WOHGM were confirmed by allelotyping of 92 SNPs mapped to a 3.16-Mb segment around RB1. Testing was performed on 84 paired samples of bladder tumor and peripheral blood DNA using SNP multiplex (SNPlex) technology according to previously published protocol (27) .
Expression, Sequencing, and Methylation Assays. We analyzed the expression, methylation, and sequences of FR genes in five cystectomies used for WOHGM, 12 bladder cancer cell lines, and 14 paired samples of adjacent urothelium and TCCs. Because these analyses showed that the two FR genes, ITM2B and P2RY5, were altered by hypermethylation and mutations, respectively, we analyzed their methylation and sequence in 195 TCCs. Sequencing of P2RY5 was also performed on peripheral blood DNA from 195 age-, gender-, and race-matched, unaffected controls. For 131 TCCs, paired nontumor DNA samples were also sequenced.
The epidemiologic analysis of 1722 G-T polymorphism involving P2RY5 was performed on peripheral blood samples from 790 patients with bladder cancer and 712 age-and sex-matched controls. The allelotyping was performed by using TaqMan SNP assay, and the data were analyzed by using STATA software as described previously (28) .
Immunohistochemical staining for RB protein was performed according to previously published protocol (29) .
Vector-Driven in Vitro Transfection Assays. We cloned ITM2BL, ITM2BS, P2RY5, and CHC1L cDNA into the mammalian expression vectors: pEGFP-c1 and pflag-c1 (Clontech, San Jose, CA). ITM2B and P2RY5 mutants were generated by site-directed mutagenesis using QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). For transient transfection, 2 ϫ 10 6 cells were suspended in 100 l of Nucleofector solution containing 2-5 g of vector DNA, and electroporated by using Nucleofector apparatus II (Amaxa Biosystems, Gaithersburg, MD). The apoptotic activity was tested by fluorescent flowcytometric DNA fragmentation and by proteolytic processing of procaspase-3 assays as described previously (30) .
